Super DC Vaccine
Phase 2Vaccine
Super DC Vaccine is one of 13 biologic programs targeting Recurrence. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Recurrence
#DrugCompanyPhaseTrials
1Aromasin
PfizerPhase 2
Tecentriq
RochePhase 2
Erleada
Johnson & JohnsonPhase 2
Kisqali
NovartisPhase 2
Femara
NovartisPhase 2
Trodelvy
GileadPhase 2
Arimidex
IIstituto Clinico Humanitas
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Phase 2
Androgen Deprivation Therapy
Johnson & JohnsonPhase 2
Chidamide
CChipscreen Biosciences, Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Super DC Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details